Inhibitor Therapeutics INTI
OTC INTI
$0.10 +0.00 (+0.00%)
At close: Sep 28, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) EV to CFO (2022 - 2023)

Updated

Inhibitor Therapeutics' EV to CFO came in at -0.09 for Q3 2023.

Analysis

Inhibitor Therapeutics (INTI) EV to CFO (2022 - 2023) Analysis & Trends

Over the trailing twelve months to Sep 30, 2023, Inhibitor Therapeutics reported EV to CFO of -3.41; for FY2022, it came in at 2.10.

  • The five-year range for quarterly EV to CFO is -0.31 (Q2 2023) to 2.10 (Q4 2022).
  • Business Quant data shows INTI's EV to CFO at -0.31 (Q2 2023), -0.04 (Q1 2023) and 2.10 (Q4 2022) in the three quarters before Q3 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Inhibitor Therapeutics 17.38 Mn 17.38 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 -0.09
Jun 30, 2023 -0.31
Mar 31, 2023 -0.04
Dec 31, 2022 2.10
API Access

Inhibitor Therapeutics EV to CFO API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=INTI&period=max&api_key=YOUR_API_KEY